ArticleJournal of nanobiotechnology2025
Nanobody Immunolabelling and three-dimensional imaging reveals spatially restricted LYVE1 expression by kidney lymphatic vessels in mice.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current progress of labeling strategies in tissue clearing for large-scale biological visualization.Frontiers in cell and developmental biology · 2026Review
- Organ-specific features of human kidney lymphatics are disrupted in chronic transplant rejection.The Journal of clinical investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundLymphatic vessels are complex three-dimensional (3D) structures that facilitate tissue fluid clearance and regulate immune responses during health and inflammation. Recent advances in wholemount immunolabelling and 3D imaging have provided insights into organ-specific heterogeneity of lymphatic vessel structure and function. However, the visualisation of lymphatic vessels deep within an intact organ remains a challenge. We hypothesised that nanobodies, single-domain antibodies raised in camelid species, would result in improved labelling of lymphatics in intact mouse organs, without loss of information due to tissue sectioning or inadequate penetration of conventional antibodies into intact tissues.
resultsWe generated and characterised nanobody clones targeting lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), a marker of lymphatic vessels. Compared with a conventional anti-LYVE1 polyclonal antibody, nanobodies were able to penetrate whole mouse organs more rapidly and at a greater depth, facilitating labelling of lymphatic vessel networks within intact mouse organs. Utilising this new tool, we found that lymphatics within the kidney, an organ in which labelling of these vessels is challenging, have spatially restricted LYVE1 expression compared with lymphatics of skin, heart, and lung. The appearance of LYVE1- kidney lymphatics coincided with the early postnatal period in mice, with single-cell RNA sequencing analysis revealing their transcriptome to be enriched for markers of either collecting vessels or lymphatic valves.
conclusionsOur findings highlight a characteristic feature of kidney lymphatic vessels, whilst providing a novel experimental tool for characterisation, isolation, or perturbation of lymphatic vessels in health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.